Cellular Biomedicine Group and GE Healthcare Life Sciences China agreed to a strategic research collaboration to co-develop particular high-quality industrial control processes in chimeric antigen receptor (CAR) T-cell and stem cell manufacturing. In connection with the particular collaboration, a joint laboratory within CBMG’ s brand new Shanghai Zhangjiang GMP facility will be established and focused on the joint research and development of a functionally integrated and automatic immunotherapy cell preparation system.
CBMG plus GE Healthcare Life Sciences China plan to develop automatic CAR T-cell and stem cell manufacturing capabilities that will build upon the accreditation of CBMG’ s GMP facilities in Shanghai, Wuxi, and Beijing. The co-development activity will aim to standardize the delivery of cellular manufacturing to potentially improve throughput, alleviate cost problems, and minimize variability in cell production, which may boost the availability of engineered cells upon commercialization.
This partnership combines CBMG’ s scientific expertise within the manufacturing of CAR T-cell and stem cell manufacturing in China and GE Healthcare’ s expertise within the design and development of innovative manufacturing technologies for the biopharmaceutical sector.
Recently, CBMG announced that its new Zhangjiang facility, together with expanded Wuxi and Beijing GMP services, will have a combined 70, 000 square feet to get development and production. This will enable CBMG to perform simultaneous clinical trials for multiple CAR T-cell plus stem cell product candidates. At full production amounts, these facilities could support the treatment of up to 10, 1000 cancer patients and 10, 000 knee osteoarthritis sufferers per year.
“ GE Healthcare‘ s collection of our facility to serve as their showcase site within China credits our GMP stature and capabilities. All of us of scientists has spent years refining our production process to become one of the very few cell therapy companies along with fully in-house integrated chemistry, manufacturing, and controls (CMC) processes for clinical grade CAR T cells, plasmid, and viral vectors bank production. We understand that among the impending barriers to adoption of immuno-oncology and originate cell therapies is the logistics in manufacturing, and we turn to take an expanded role both domestically and possibly globally. We are pleased to be in a strategic partnership with GENERAL ELECTRIC Healthcare and look forward to showcasing our facilities as well as the mutual benefit this joint laboratory will bring, ” mentioned Tony Liu, CEO, CBMG.
“ Cellular therapy as an industry continues to refine and evolve within China with vast potential to change the ways different diseases are treated. GE continues investing in technologies plus services aimed at the thriving cell therapy industry having a firm commitment of making these promising therapies accessible via successful industrialization. We are pleased to partner with CBMG, a leader within CAR T-cell and stem cell development in China and taiwan and to take advantage of their excellent CMC cell production features, ” added Li Qing, general manager, GE Health care Life Sciences, Greater China.